STOCK TITAN

Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Annexon (Nasdaq: ANNX), a clinical-stage biopharmaceutical company, announced that CEO Douglas Love will present at the 2022 Jefferies Healthcare Conference on June 9, 2022, at 10:30 a.m. ET in New York City. The event is part of Annexon's effort to showcase its innovative complement medicines targeting autoimmune, neurodegenerative, and ophthalmic disorders. A live webcast will be available on the company's Investors page, with a 30-day replay option.

Annexon is developing a diverse pipeline aimed at treating classical complement-mediated diseases.

Positive
  • None.
Negative
  • None.

BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, Esq., president and chief executive officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m. ET in New York City.

A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

About Annexon
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company that aims to bring game-changing medicines to patients with classical complement-mediated diseases of the body, brain and eye. The classical complement cascade is a seminal pathway within the immune system that anchors and drives a host of autoimmune, neurodegenerative and ophthalmic diseases. Annexon is advancing a new class of complement medicines targeting the early classical cascade and all downstream pathway components that contribute to disease, while selectively preserving the beneficial immune functions of other complement pathways. Annexon is rigorously developing a pipeline of diversified product candidates across multiple mid- to late- stage clinical trials, with clinical data anticipated throughout 2022 and 2023. For more information, visit www.annexonbio.com.

Contact:

Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com


FAQ

When is Annexon presenting at the Jefferies Healthcare Conference in 2022?

Annexon will present at the Jefferies Healthcare Conference on June 9, 2022, at 10:30 a.m. ET.

Who is the CEO of Annexon presenting at the conference?

The CEO of Annexon presenting at the conference is Douglas Love.

Where can I watch the Annexon presentation from the Jefferies Healthcare Conference?

You can watch the Annexon presentation live on their Investors page, and a replay will be available for 30 days.

What type of medicines is Annexon developing?

Annexon is developing a new class of complement medicines for autoimmune, neurodegenerative, and ophthalmic disorders.

What is the stock symbol for Annexon?

The stock symbol for Annexon is ANNX.

Annexon, Inc.

NASDAQ:ANNX

ANNX Rankings

ANNX Latest News

ANNX Stock Data

553.22M
98.66M
0.5%
106.1%
7.35%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BRISBANE